Precision oncology diagnostics firm NucleoBio and CLIA-certified PreCheck Health Services have entered a strategic collaboration to validate and process Prostac, a qPCR-based composite assay for prostate cancer. Prostac measures expression levels of long noncoding RNA biomarkers from the PVT1 gene, with particular sensitivity in men of African ancestry, demonstrating 100% sensitivity and specificity in preliminary lab studies. Integrating machine learning to generate predictive scores, this non-invasive assay represents a significant step forward in early prostate cancer detection and stratification.